Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.1 USD | +13.58% | +10.00% | -58.96% |
Valuation
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 3.529 | 5.515 | 3.833 | - | - |
Enterprise Value (EV) 1 | 3.529 | 5.515 | 3.833 | 3.833 | 3.833 |
P/E ratio | -2.1 x | - | - | - | - |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | 14.5 x | - | - | - |
EV / Revenue | - | 14.5 x | - | - | - |
EV / EBITDA | - | - | - | - | - |
EV / FCF | - | - | -0.35 x | -0.24 x | -0.18 x |
FCF Yield | - | - | -287% | -417% | -548% |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 13.5 | 2,620 | 4,385 | - | - |
Reference price 2 | 260.6 | 2.105 | 0.8742 | 0.8742 | 0.8742 |
Announcement Date | 28/04/23 | 19/04/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | 0.381 | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | - | -8.014 | -12.66 | -16.95 | -22.74 |
Operating Margin | - | -2,103.41% | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - |
Net income | -7.656 | - | - | - | - |
Net margin | - | - | - | - | - |
EPS | -124.0 | - | - | - | - |
Free Cash Flow 1 | - | - | -11 | -16 | -21 |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 28/04/23 | 19/04/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
---|---|---|---|---|
Net sales 1 | 0.298 | 0.083 | - | - |
EBITDA | - | - | - | - |
EBIT 1 | - | -3.77 | -5.617 | -7.038 |
Operating Margin | - | -4,542.17% | - | - |
Earnings before Tax (EBT) | - | - | - | - |
Net income | -3.568 | - | - | - |
Net margin | -1,197.32% | - | - | - |
EPS | - | - | - | - |
Dividend per Share | - | - | - | - |
Announcement Date | 29/09/23 | 19/04/24 | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow 1 | - | - | -11 | -16 | -21 |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex 1 | - | - | 0.01 | 0.05 | 0.11 |
Capex / Sales | - | - | - | - | - |
Announcement Date | 28/04/23 | 19/04/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-58.96% | 4.82M | |
+5.33% | 111B | |
+12.11% | 106B | |
-12.56% | 22.24B | |
-3.44% | 21.25B | |
-5.80% | 18.97B | |
-35.21% | 18.52B | |
-10.86% | 16.81B | |
+37.57% | 12.54B | |
-26.24% | 8.09B |
- Stock Market
- Equities
- BDRX Stock
- Financials Biodexa Pharmaceuticals Plc